These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 32896668)

  • 1. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
    Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P
    Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin Does Not Directly Affect Human α or β Cells.
    Dai C; Walker JT; Shostak A; Bouchi Y; Poffenberger G; Hart NJ; Jacobson DA; Calcutt MW; Bottino R; Greiner DL; Shultz LD; McGuinness OP; Dean ED; Powers AC
    Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32428240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
    Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
    Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No direct effect of SGLT2 activity on glucagon secretion.
    Kuhre RE; Ghiasi SM; Adriaenssens AE; Wewer Albrechtsen NJ; Andersen DB; Aivazidis A; Chen L; Mandrup-Poulsen T; Ørskov C; Gribble FM; Reimann F; Wierup N; Tyrberg B; Holst JJ
    Diabetologia; 2019 Jun; 62(6):1011-1023. PubMed ID: 30903205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
    Solini A; Sebastiani G; Nigi L; Santini E; Rossi C; Dotta F
    Diabetes Metab; 2017 Dec; 43(6):512-520. PubMed ID: 28499695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
    Tanday N; Irwin N; Flatt PR; Moffett RC
    Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
    Bonner C; Kerr-Conte J; Gmyr V; Queniat G; Moerman E; Thévenet J; Beaucamps C; Delalleau N; Popescu I; Malaisse WJ; Sener A; Deprez B; Abderrahmani A; Staels B; Pattou F
    Nat Med; 2015 May; 21(5):512-7. PubMed ID: 25894829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.
    Saponaro C; Mühlemann M; Acosta-Montalvo A; Piron A; Gmyr V; Delalleau N; Moerman E; Thévenet J; Pasquetti G; Coddeville A; Cnop M; Kerr-Conte J; Staels B; Pattou F; Bonner C
    Diabetes; 2020 May; 69(5):902-914. PubMed ID: 31896553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition.
    Capozzi ME; Coch RW; Koech J; Astapova II; Wait JB; Encisco SE; Douros JD; El K; Finan B; Sloop KW; Herman MA; D'Alessio DA; Campbell JE
    Diabetes; 2020 May; 69(5):882-892. PubMed ID: 32005706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
    Wang MY; Yu X; Lee Y; McCorkle SK; Chen S; Li J; Wang ZV; Davidson JA; Scherer PE; Holland WL; Unger RH; Roth MG
    Proc Natl Acad Sci U S A; 2017 Jun; 114(25):6611-6616. PubMed ID: 28584109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.
    Vergari E; Knudsen JG; Ramracheya R; Salehi A; Zhang Q; Adam J; Asterholm IW; Benrick A; Briant LJB; Chibalina MV; Gribble FM; Hamilton A; Hastoy B; Reimann F; Rorsman NJG; Spiliotis II; Tarasov A; Wu Y; Ashcroft FM; Rorsman P
    Nat Commun; 2019 Jan; 10(1):139. PubMed ID: 30635569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells.
    Timper K; Dalmas E; Dror E; Rütti S; Thienel C; Sauter NS; Bouzakri K; Bédat B; Pattou F; Kerr-Conte J; Böni-Schnetzler M; Donath MY
    Gastroenterology; 2016 Jul; 151(1):165-79. PubMed ID: 26971825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
    Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
    Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
    Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
    Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered pancreatic islet morphology and function in SGLT1 knockout mice on a glucose-deficient, fat-enriched diet.
    Mühlemann M; Zdzieblo D; Friedrich A; Berger C; Otto C; Walles H; Koepsell H; Metzger M
    Mol Metab; 2018 Jul; 13():67-76. PubMed ID: 29859847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibition and glucagon secretion in humans.
    Saponaro C; Pattou F; Bonner C
    Diabetes Metab; 2018 Nov; 44(5):383-385. PubMed ID: 30017776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion.
    Abels M; Riva M; Bennet H; Ahlqvist E; Dyachok O; Nagaraj V; Shcherbina L; Fred RG; Poon W; Sörhede-Winzell M; Fadista J; Lindqvist A; Kask L; Sathanoori R; Dekker-Nitert M; Kuhar MJ; Ahrén B; Wollheim CB; Hansson O; Tengholm A; Fex M; Renström E; Groop L; Lyssenko V; Wierup N
    Diabetologia; 2016 Sep; 59(9):1928-37. PubMed ID: 27338624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
    Hogan MF; Hackney DJ; Aplin AC; Mundinger TO; Larmore MJ; Castillo JJ; Esser N; Zraika S; Hull RL
    J Endocrinol; 2021 Feb; 248(2):95-106. PubMed ID: 33337344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
    Park SH; Belcastro E; Hasan H; Matsushita K; Marchandot B; Abbas M; Toti F; Auger C; Jesel L; Ohlmann P; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2021 Mar; 20(1):65. PubMed ID: 33726768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.